{"id":341,"date":"2015-02-20T08:10:54","date_gmt":"2015-02-20T13:10:54","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=341"},"modified":"2015-02-20T08:22:01","modified_gmt":"2015-02-20T13:22:01","slug":"syndicate-schedule-week-of-february-23","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/syndicate-schedule-week-of-february-23\/","title":{"rendered":"Syndicate Schedule: Week of February 23"},"content":{"rendered":"<h2>Wednesday<\/h2>\n<p><a href=\"https:\/\/www.ipoboutique.com\/cgi\/info\/WowoLimited-WOWO-info.php\" target=\"_blank\"><strong>Wowo Limited (Nasdaq: WOWO)<\/strong> <\/a>&#8211; Axiom is running the deal that is to sell 6.0 million shares at an initial range of $9.00-$11.00.<a href=\"https:\/\/www.ipoboutique.com\/cgi\/info\/WowoLimited-WOWO-info.php\" target=\"_blank\"><br \/>\n<\/a><\/p>\n<h2>Friday<\/h2>\n<p><strong>Actavis (Nasdaq: ACT)<\/strong> &#8211; The company is pursuing a secondary with concurrent offerings totaling $8.4 billion, comprising $4.2 billion of Ordinary Shares and $4.2 billion of Mandatory Convertible Preferred Shares, Series A,\u00a0each in a separate registered public offering, subject to market and other conditions. The sale is <a href=\"http:\/\/www.wsj.com\/articles\/actavis-to-sell-8-4-billion-in-shares-to-fund-allergan-acquisition-1424352945\" target=\"_blank\">to fund the acquisition of Allergan<\/a> that was announced in late 2014.<\/p>\n<p><em>IPOBoutique.Com provides comprehensive research, ratings and daily advisories on new issues hitting the IPO market. To subscribe to IPOBoutique\u2019s service: <a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\" target=\"_blank\">click here. <\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wednesday Wowo Limited (Nasdaq: WOWO) &#8211; Axiom is running the deal that is to sell 6.0 million shares at an initial range of $9.00-$11.00. Friday Actavis (Nasdaq: ACT) &#8211; The company is pursuing a secondary with concurrent offerings totaling $8.4 billion, comprising $4.2 billion of Ordinary Shares and $4.2 billion of Mandatory Convertible Preferred Shares,[&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24,35],"tags":[135,140],"class_list":["post-341","post","type-post","status-publish","format-standard","hentry","category-ipo","category-secondary-offerings","tag-act","tag-wowo"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=341"}],"version-history":[{"count":2,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/341\/revisions"}],"predecessor-version":[{"id":343,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/341\/revisions\/343"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}